Increase of mitochondrial dysfunction and glycolysis by decreased NEFH. by Myoung Sook Kim (91321)

<i>Syx5</i> suppression in <i>Drosophila</i> S2 cells decreases copper accumulation. by Melanie Norgate (234832)

Calpeptin treatment decreases cell density and proliferation. by Daniela M. Santos (211055)

Chemical Inhibition of eEF1A-1 Peptide Elongation Activity Decreases Palmitate-Induced Cell Death. by Alexandra M. Stoianov (759321)

Tranilast decreases RANKL-induced ROS level. by Tien Van Phan (583324)

COG annotation of differentially abundant proteins of three genotypes of <i>Lolium perenne</i> (fold increase>1.5, fold decrease<0.5, <i>P</i> < 0.05). by Fatemeh Raeisi Vanani (8991491)

Tranilast decreases OC formation induced by RANKL. by Tien Van Phan (583324)

Incubation of <i>T</i>. <i>brucei</i> with Pol I transcription inhibitors results in a dramatic decrease in VEX1 foci. by Louise E. Kerry (3815164)

T198A/G substitution markedly decrease p27 protein stability. by Monica Schiappacassi (227672)

Fig 5 - by Felix Bosch (10024550)

AGE-modification of laminin leads to a decrease in Kir4.1 function. by Kayla Thompson (4885036)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study by Asita Wongprikorn (2837378)

“…At 12 weeks of treatment with pitavastatin compared to placebo; mean [95% confidence interval (CI)] total cholesterol (TC) was 207 (187.3, 226.8) mg/dL vs 246.3 (226.5, 266) mg/dL (<i>p</i> <0.001); mean (95% CI) triglyceride (TG) was 351.3 (193.2, 509.4) mg/dL vs 279.1 (121, 437.2) mg/dL (<i>p</i> = 0.269); mean (95% CI) high density lipoprotein (HDL) was 45.3 (40.4, 50.2) mg/dL vs 44.2 (39.3, 49.1) mg/dL (<i>p</i> = 0.354); and mean (95% CI) low density lipoprotein (LDL) was 113.2 (100.4, 126) mg/dL vs 145.6 (132.8, 158.4) mg/dL (<i>p</i> <0.001). …”

Overexpression of PLIC-1 decreased Trif abundance in a Nocodazole-sensitive manner. by Nabanita Biswas (349647)

The effects of TDBP-TAZTO (5 and 50 mg/kg) on spatial learning and memory in rats in the Morris water test. by Liang Ye (6646)

“…Data ate expressed as mean ± SE (n = 10/group). ^a<i>p</i> < 0.05, TDBP-TAZTO 5 mg/kg group vs. control group; ^b<i>p</i> < 0.05, TDBP-TAZTO 50 mg/kg group vs. control group.…”

The functional half-life of WNV decreases in the presence of virus-specific antibody. by Kimberly A. Dowd (129927)

 Performance of NLLSS under the validation framework of LOOCV, 10-fold CV, 5-fold CV, and 3-fold CV, which have demonstrated the NLLSS has a reliable and robust performance. by Xing Chen (140292)

Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in cortex. by Martial Caillaud (6383672)

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in hippocampus. by Martial Caillaud (6383672)